Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,627.39
(
-1.32%
)
US TECH 100
23,834.20
(
-1.24%
)
Dow Jones
46,213.91
(
-1.66%
)
Brent Oil
106.65
(
5.96%
)
Bitcoin
71,125.97
(
-3.81%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 73877

Monday, 10/25/2010 7:06:46 AM

Monday, October 25, 2010 7:06:46 AM

Post# of 257253
Rebif delays conversion from CIS to MS in phase-3 study:

http://www.merck.de/en/media/extNewsDetail.html?newsId=BE4AD7B22B3C0C39C12577C600734F7D&newsType=1

The primary endpoint was time to conversion. For patients in the thrice-weekly dosing arm (44mcg per dose), HR=0.49 and p<0.00001. For patients in the once-weekly dosing arm (also 44mcg per dose), HR=0.69 and p=0.008. The full dataset will be presented at an unspecified medical conference.

Copaxone is already approved in this indication based on pivotal data broadly similar to the above data for Rebif (#msg-55641123).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now